Technical Analysis for SAGE - Sage Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 156.72 -0.80% -1.26
SAGE closed down 0.8 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical SAGE trend table...

Date Alert Name Type % Chg
Mar 22 20 DMA Support Bullish 0.00%
Mar 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 22 Boomer Buy Setup Bullish Swing Setup 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 21 Crossed Above 20 DMA Bullish -0.80%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -0.80%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.80%
Mar 21 Bollinger Band Squeeze Range Contraction -0.80%

Older signals for SAGE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.
Chemistry Biopharmaceutical Physical Sciences Drugs Antidepressants Gabaa Receptor Positive Allosteric Modulators Anticonvulsants Adjunctive Therapy Neurosteroids
Is SAGE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 188.82
52 Week Low 79.88
Average Volume 569,982
200-Day Moving Average 139.2381
50-Day Moving Average 147.3784
20-Day Moving Average 155.6655
10-Day Moving Average 156.293
Average True Range 6.4373
ADX 31.53
+DI 22.5419
-DI 9.1824
Chandelier Exit (Long, 3 ATRs ) 143.8881
Chandelier Exit (Short, 3 ATRs ) 164.6819
Upper Bollinger Band 161.6262
Lower Bollinger Band 149.7048
Percent B (%b) 0.59
BandWidth 7.658344
MACD Line 2.6941
MACD Signal Line 3.3871
MACD Histogram -0.6929
Fundamentals Value
Market Cap 5.86 Billion
Num Shares 37.4 Million
EPS -6.09
Price-to-Earnings (P/E) Ratio -25.73
Price-to-Sales 0.00
Price-to-Book 8.73
PEG Ratio 0.72
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 164.09
Resistance 3 (R3) 163.93 161.31 162.86
Resistance 2 (R2) 161.31 159.44 161.39 162.45
Resistance 1 (R1) 159.02 158.28 157.71 159.18 162.04
Pivot Point 156.40 156.40 155.75 156.48 156.40
Support 1 (S1) 154.11 154.53 152.80 154.27 151.40
Support 2 (S2) 151.49 153.37 151.57 150.99
Support 3 (S3) 149.20 151.49 150.58
Support 4 (S4) 149.36